(Q43527880)

English

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 November 2017

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program (English)

1 reference

Europe PubMed Central

24 November 2017

arterial hypertension

1 reference

based on heuristic

inferred from title

Marius M Hoeper

2

1 reference

Europe PubMed Central

24 November 2017

7

object named as

Marc Humbert

1 reference

Europe PubMed Central

24 November 2017

3

object named as

David G Kiely

1 reference

Europe PubMed Central

24 November 2017

author name string

Maurice Beghetti

1

1 reference

Europe PubMed Central

24 November 2017

Joern Carlsen

4

1 reference

Europe PubMed Central

24 November 2017

Barbara Schwierin

5

1 reference

Europe PubMed Central

24 November 2017

Eleanor S Segal

6

1 reference

Europe PubMed Central

24 November 2017

language of work or name

0 references

publication date

1 August 2008

1 reference

Europe PubMed Central

24 November 2017

Pediatric Research

1 reference

Europe PubMed Central

24 November 2017

64

1 reference

Europe PubMed Central

24 November 2017

2

1 reference

Europe PubMed Central

24 November 2017

200-204

1 reference

Europe PubMed Central

24 November 2017

https://scigraph.springernature.com/pub.10.1203/pdr.0b013e318179954c

0 references

Cellular and molecular pathobiology of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Pulmonary arterial hypertension in children

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Outcomes in children with idiopathic pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Epoprostenol treatment in children with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Vasodilator therapy for primary pulmonary hypertension in children

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Survival with first-line bosentan in patients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Effects of long-term bosentan in children with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Response to bosentan in children with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Primary pulmonary hypertension in childhood

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Pharmacoepidemiology: current status, prospects, and problems

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Identifiers

10.1203/PDR.0B013E318179954C

1 reference

Europe PubMed Central

24 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43527880&oldid=2098118985"